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Purpose: To determine the pattern of increase in intraocular pressure (IOP) following 
intravitreal triamcinolone acetonide (IVTA) and identify possible risk factors associated with 
this rise in IOP.
Methods: We carried out a retrospective review of records for 185 patients (226 eyes) who 
received 4 mg of IVTA at the American University of Beirut Medical Center and Hotel Dieu 
de France eye clinics between 2003 and 2005
Results: Mean follow-up was 8.17 months (range 6 to 24 months). The mean number of IVTA 
injections per eye was 1.31 ± 0.69. The mean IOP increased after the ﬁ  rst IVTA injection from 
15.04 ± 3.18 mmHg at baseline to a mean maximum of 17.20 ± 5.75 mmHg (p  0.0001, paired 
t-test) at month 3 of follow-up with a return to mean baseline IOP (15.49 ± 4.79 mmHg) at 
month 12. Fifty nine of 226 eyes showed IOP higher than 21 mmHg during follow-up. Nine eyes 
started to have IOP greater than 21 mmHg, 6 to 12 months after a single injection. Intraocular 
pressure lowering medications were started when IOP exceeded 25 mmHg in 15 of the 226 
eyes studied. No risk factors have been found to predict this IOP rise
Conclusions: IOP elevation can occur in a signiﬁ  cant number of eyes receiving 4 mg of IVTA. 
This phenomenon seems to be transient and a small number of eyes required treatment during 
this period. Eyes that received IVTA need to be monitored for IOP changes especially during 
the ﬁ  rst 3 months, but the IOP may still rise 6 months and even 12 months after a single injec-
tion. This study did not show any risk factor that may predict this IOP rise
Keywords: intravitreal triamcinolone acetonide, intraocular pressure elevation, diabetic macular 
edema, choroidal neovascular membrane due to age-related macular degeneration, central retinal 
vein occlusion, Branch retinal vein occlusion, Uveitis
Introduction
Intravitreal corticosteroids play an effective role in reducing inﬂ  ammatory intraocular 
conditions (Wingate and Beaumont 1999; Antcliff et al 2001; Jonas et al 2001a, 2001b, 
2003b; Degenring and Jonas 2003; Degenring et al 2003; Gillies et al 2003; Spaide et al 
2003; Massin et al 2004; Smithen et al 2004). This anti-inﬂ  ammatory action is exerted 
by inhibiting the formation of major inﬂ  ammatory mediators such as leukotrienes and 
prostaglandins (Edelman et al 2005; Tamura et al 2005). Moreover, corticosteroids also 
decrease cellular permeability by inhibiting the expression of several endothelial growth 
factors and intracellular adhesion molecules (Edelman et al 2005; Tamura et al 2005).
Among the several routes of ocular corticosteroid delivery, the intravitreal route 
was found to insure adequate drug penetration and bioavailability (Jonas 2002a, 2002b, 
2004; Beer et al 2003). Moreover, the crystalline form of corticosteroids ensures a 
longer period of intraocular availability.
Intravitreal injection of triamcinolone acetonide (IVTA) has been used successfully 
in the treatment of macular edema caused by diabetes mellitus (Jonas et al 2001b; Clinical Ophthalmology 2008:2(2) 270
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Massin et al 2004), pseudophakia (Jonas et al 2003b), central 
retinal vein occlusion (Degenring et al 2003), and uveitis 
(Antcliff et al 2001; Degenring and Jonas 2003). It was also 
effective against various vasoproliferative conditions such 
as proliferative diabetic retinopathy (Jonas et al 2001a), age 
related macular degeneration (Gillies et al 2003), and iris 
neovascularization (Jonas et al 2001b).
Several side effects are well known and reported in IVTA 
treatment, such as cataract formation and post-injection endo-
phthalmitis (infectious or sterile) (Benz et al 2003; Jonas et al 
2003a; Ozkiris and Erkilic 2005; Jonas et al 2005). The most 
commonly reported side effect of IVTA is a transient rise in 
intraocular pressure (IOP) (Wingate and Beaumont 1999; 
Bakri and Beer 2003; Jonas et al 2003c; Massin et al 2004). 
Ozkiris and Erkilic (2005) reported a rise in IOP above 21 
mmHg in 21% of the eyes receiving 8 mg of IVTA, while 
Jonas and colleagues (2005) reported a similar IOP rise in 
41% of patients receiving a 20 mg dose. This IOP rise was 
found to be transient whereby the mean IOP at 9 months after 
IVTA was not statistically different from mean pre-injection 
values. Bakri and Beer (2003) reported a mean time of 4.1 
weeks for the rise in IOP with maximum IOP elevation 6.6 
weeks after 4 mg IVTA. A similar pattern of IOP rise was 
reported in several other studies (Wingate et al 1999; Jonas 
et al 2003c; Massin et al 2004; Smithen et al 2004).
Jonas and colleagues (2005) found that young age was 
the only risk factor for elevated IOP after 20 mg IVTA. A 
literature search did not reveal similar studies to determine 
risk factors for elevated IOP after 4 mg IVTA. The purpose 
of our study is to determine the pattern of increase in the 
IOP following IVTA, and to identify possible risk factors 
associated with this increase.
Methods
This study was a retrospective review of all cases that 
received IVTA at the American University of Beirut Medical 
Center and Hotel Dieu de France eye clinics between 2003 
and 2005. Only patients with at least 6 months of follow up 
were included. Those with inadequate follow up or docu-
mentation and prior vitrectomy were excluded.
All patients received the treatment knowing that this was 
an off-label use of triamcinolone acetonide and signed an 
informed consent. Baseline data included age, gender, pha-
kic status, refractive error, previous ocular diseases includ-
ing history of glaucoma, and previous medical or surgical 
interventions. Patients had a complete eye examination that 
included best corrected visual acuity (BCVA), Goldman 
applanation tonometery, anterior segment assessment, and 
dilated fundus examination. Fundus photography, OCT or 
ﬂ  uorescein angiography were done as indicated.
All eyes received an intravitreal injection of 4 mg of 
crystalline triamcinolone acetonide (Kenacort, Myers Squibb, 
Athens, Greece). This was done as an ofﬁ  ce procedure. The 
eye was prepared with 5% Povidone-iodine solution then lido-
caine 1% was given sub-conjunctivally in the infero-temporal 
quadrant where the IVTA injection was intended. The IVTA 
injection was given 3.5 mm posterior to the limbus through the 
infero-temporal pars plana using a 27 gauge needle. Paracen-
tesis was done if the optic nerve head was not well perfused 
20 minutes after giving the IVTA or if the IOP remained more 
than 25 mmHg. Patients received ciproﬂ  oxacin drops (Ciloxan, 
Alcon, Puurs, Belgium) 3 times per day for 3 days.
The IOP was measured before the injection then at 1, 4, and 
12 weeks after the injection, and every 3 months thereafter. 
A complete eye examination was done at the 4- and 12-week 
visits and then every 3 months. Topical IOP lowering agents 
were started if the IOP was more than 25 mmHg. Two or more 
medications were added if necessary to control the IOP. The 
initial medication used was ﬁ  xed combination of dorzolamide 
hydrochloride-timolol maleate (Cosopt, MSD, Haarlem, Neth-
erland). Travoprost (Travatan, Alcon, Fort Worth, USA), bri-
monidine tartrate (Alphagan, Allergan, Westport, Co. Mayo, 
Ireland) and acetazolamide (Diamox, Lederle, Maidenhead 
Berks, UK) were sequentially added in eyes with suboptimal 
IOP on Cosopt alone. Filtering surgery was done only in 
refractory cases on 3 or more medications.
Statistical analysis of the collected data was done 
using SPSS 13.0 software. The Student t-test was used to 
assess sample mean differences of the intraocular pressure. 
Pearson’s correlation test was applied to evaluate associa-
tions between different variables and to adjust for inter-eye 
correlation. The statistical analysis was performed with a 
95% conﬁ  dence interval.
Results
One hundred and eighty ﬁ  ve patients (81 women and 104 
men) were included in the study for a total of 226 eyes. The 
mean age was 64.2 years (range 22 to 89 years), and the 
mean refractive error was –0.27 diopters (range –7.25 to 
+8.00 diopters). The mean follow-up was 8.17 months (range 
6 to 24 months). All 185 patients (226 eyes) had 6-month 
follow-up. However, by 12 and 24 months there were 110 
eyes and 40 eyes, respectively.
Indications for IVTA treatment were clinically signiﬁ  cant 
diabetic macular edema (CSME, n = 146 eyes), choroidal 
neovascular membrane associated with age-related macular Clinical Ophthalmology 2008:2(2) 271
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degeneration (CNV due to AMD, n = 61 eyes), central retinal 
vein occlusion (CRVO, n = 10 eyes), branch retinal vein 
occlusion (BRVO, n = 6 eyes), and uveitis (n = 3 eyes).
In the study group, 46 (20.35%) eyes had intraocular 
neovascular diseases related to diabetic retinopathy or cen-
tral retinal vein occlusion. History of retinal laser surgeries 
was recorded in 208 eyes (92.03%). In addition, 109 eyes 
(48.23%) had previous cataract surgeries with intraocular 
lens insertion. The main medical conditions noted among 
patients were diabetes mellitus (n = 127 patients), and hyper-
tension (n = 87 patients).
The mean number of IVTA injections per eye was 1.31 
± 0.69 injections, distributed as follows: 173 eyes received 
1 injection, 42 eyes received 2 injections, 8 eyes received 3 
injections, 2 eyes received 5 injections, and 1 eye received 
6 injections.
IOP measurements were obtained at baseline, then at week 
1 and month 1 post-injection, followed by evaluations every 3 
months. The mean IOP increased after the ﬁ  rst IVTA injection 
from 15.04 ± 3.18 mmHg at baseline to a mean maximum of 
17.20 ± 5.75 mmHg (p  0.0001, paired t-test) at month 3 of 
follow-up (Figure 1). A return to mean baseline IOP (15.49 ± 
4.79 mmHg) was observed at month 12 of follow-up. Table 1 
shows the distribution of IOP at different time segments. Sev-
enty four of 226 eyes (33.74%) or 67 of 185 patients (36.21%) 
had an IOP rise greater than 5 mmHg from baseline.
Of the 226 eyes included in the study, 59 eyes (26.1%) 
showed IOP measurements higher than 21 mmHg during 
follow-up. The mean baseline IOP was 16.57 ± 3.56 mmHg. 
The difference between the mean baseline and the mean 
maximal IOP (22.22 ± 6.81 mmHg), which was noted at 3 
months post-injection, was 5.64 ± 7.69 mmHg (p  0.0001). 
A return to a mean normal baseline intraocular pressure 
(16.35 ± 5.43 mmHg) was noted at month 12 of follow-up. 
Similarly, the mean time for an IOP rise greater than 5 mmHg 
was 3.75 ± 3.20 months. This 5 mmHg rise was noted in 45 
of the 59 eyes (76.27%) and was distributed as follows: 12 
of 59 eyes (20.33%) at month 1, 21 of 59 eyes (35.59%) at 
month 3, 10 of 59 eyes (16.94%) at month 6, 1 of 47 eyes 
(2.12%) at month 9 and 1 of 26 eyes (3.84%) at month 12 of 
follow-up. Of the 59 eyes that developed IOP greater than 
21 mmHg, 44 eyes received only 1 injection. Nine of these 
44 eyes (20.45%) started having IOP greater than 21 mmHg 
more than 3 months after the injection (Figure 2).
There was no significant difference in IOP change 
between patients who had baseline IOP  16 mmHg and 
those who had baseline IOP  16 mmHg at 3 months 
(p = 0.87) and 12 months (p = 0.44) of follow-up.
Eleven (4.86%) of the 226 eyes included in the study 
presented with glaucoma conditions comprising of primary 
open angle (n = 6), neovascular (n = 4), and phacolytic 
(n = 1) glaucoma. The rise in IOP did not vary signiﬁ  cantly 
Figure 1 Bar graph of mean intraocular pressure (IOP, mmHg) for the entire study group versus follow-up time in months.
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between the glaucoma subgroup (2.10 ± 3.90 mmHg) and the 
remaining eyes (2.16 ± 6.42 mmHg) at month 3 of follow-up 
(p = 0.902). In addition, there was no statistically signiﬁ  cant 
difference in the change in IOP between phakic and pseudo-
phakic status (p = 0.421).
Intraocular pressure lowering medications were started 
when the IOP exceeded 25 mmHg in 15 (6.63 %) of the 226 
eyes studied. In this subgroup, anti-glaucoma therapy was given 
to control IOP increase at month 1 after the ﬁ  rst IVTA injection 
in 3 eyes (IOP range: 28–42 mmHg), at month 3 after the ﬁ  rst 
IVTA injection in 7 eyes (IOP range: 28–38 mmHg), and at 
month 6 after a second IVTA injection in 5 eyes (IOP range: 
25–40 mmHg). The intraocular pressure for these 15 eyes had 
a mean of 17.20 ± 3.64 mmHg at baseline, reached a maximal 
mean of 24.28 ± 9.07 mmHg (p = 0.016) at month 3 of follow-
up, and then returned to mean baseline intraocular pressure of 
17.87 ± 8.77 mmHg (p = 0.928) at month 12 of follow-up.
Statistical analysis was performed to uncover a correla-
tion between the elevation in IOP after IVTA injection and 
the different parameters included in the study. Using the 
bivariate logistic analysis (Pearson’s correlation), we found 
no signiﬁ  cant associations between the increase in IOP and 
age, refractive error and the number of IVTA injections. 
Furthermore, a univariate analysis of variance showed no 
signiﬁ  cant correlations between increase in IOP and gender, 
glaucoma, phakic status, diabetes, hypertension, and the vari-
ous underlying ocular diseases (BRVO, CNV due to AMD, 
CRVO, DME, and uveitis) (Table 2).
Discussion
Because of its long availability of up to 1.5 years (Jonas 
2002a, 2002b, 2004; Beer et al 2003), IVTA has been used 
increasingly and studied in the treatment of many intraocular 
conditions, such as proliferative, edematous and neovascular 
Table 1 Pattern of elevated intraocular pressure after intravitreal injection of 4 mg triamcinolone acetonide
  Percentage of patients over time
IOP (mmHg)  Baseline  1 Month  3 Months  6 Months  9 Months  12 Months  24 Months
21  97.34%  89.38%  84.95%  88.49% 86.82% 94.54%  90%
21–25 2.21%  4.42%  8.4%  7.07% 8.38% 0.90%  5%
25–30 0.44%  3.53%  2.21%  3.53% 1.19% 1.81%  5%
30–35 0  1.76%  2.21%  0.44% 2.65% 2.72%  0
35–40  0  0  1.76%  0 0 0  0
40–45 0  0.88%  0  0.44% 0  0  0
45  0  0  0.44%  0 0 0  0
Figure 2 Bar graph representing the number of patients at various follow-ups with elevated intraocular pressure (IOP) after a single IVTA injection.
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diseases (Wingate and Beaumont 1999; Antcliff et al 2001; 
Jonas 2001a, 2001b; Degenring and Jonas 2003; Degenring 
et al 2003; Gillies et al 2003; Jonas et al 2003b; Spaide et al 
2003; Massin et al 2004; Smithen et al 2004). In this study up 
to 26% of eyes had intraocular pressure rise greater than 21 
mmHg during follow up. The mean IOP peaked at 3 months 
then returned to normal at month 12 of follow up. Massin 
and colleagues (2004) found that with 4 mg IVTA injection, 
IOP exceeded 25 mmHg in 50% of eyes, and Smithen and 
colleagues (2004) reported an IOP increase in 40% of patients 
who received a single IVTA injection. In a study by Jonas 
and colleagues (2005), IOP greater than 21 mmHg during a 
3 month follow up period was noted in 41% of eyes given 
20 mg IVTA. This higher incidence of elevated IOP in the 
Jonas study may reﬂ  ect the higher dose of IVTA.
Our data shows that IOP increased by more than 5 mmHg 
from baseline in 32.7% of the eyes or 36.2% of the patients. 
Wingate and Beaumont (1999) reported a similar rise in IOP 
in 30% of patients who received the same IVTA dose. Bakri 
and Beer (2003), on the other hand, reported a similar rise in 
49% of eyes receiving 4 mg of IVTA.
Armaly (1963) reported 46% of glaucoma eyes increased 
IOP more than 16 mmHg with 0.1% dexamethasone eye drops. 
The glaucoma subgroup of patients in this study had a nonsig-
niﬁ  cant rise in IOP at 6 months post injection with a return to 
baseline at 1 year post injection. The patients involved were 
already on antiglaucoma treatment which may explain why 
they did not have a more pronounced rise in the IOP as may be 
expected. However, it is note worthy that if there was a larger 
number of glaucoma patients in the study, the percentage of 
patients with IOP rise may have been greater.
Despite the latter, the beneﬁ  t of IVTA injections should 
be meticulously weighed in glaucoma patients against the risk 
of signiﬁ  cant IOP increase. In our study, glaucoma patients 
were directly involved in the treatment decision by taking 
into consideration their potential visual improvement and 
especially their expectations from the treatment.
Several variables were studied as risk factors for IOP 
rise. These were namely: age, gender, refractive error, and 
number of IVTA injections, various reasons for IVTA injec-
tion, phakic status, diabetes, hypertension and glaucoma. No 
signiﬁ  cant correlation was noticed with these variables. The 
absence of correlation with diabetes is in agreement with 
previous clinical trials where this correlation was investigated 
(Palmberg 2001).
The major limitations of this study are mainly the ret-
rospective nature of the data and the loss of follow up of 
many patients over time. Only half the patients (110 of 226 
eyes) completed 1 year of follow up, while only 40 patients 
completed 2 years. Some patients who were lost to follow 
up may potentially have had an increase in their IOP and 
thus would have altered the percentage of patients with IOP 
rise. However, the rise in IOP occurred mainly during the 
ﬁ  rst 6 months post IVTA injection (the ﬁ  rst 3 months to be 
more precise), where all the eyes were still presenting for 
follow up.
In conclusion, our data shows that IOP elevation can 
occur in a signiﬁ  cant number of eyes receiving 4 mg of 
IVTA. This phenomenon seems to be transient and a small 
number of eyes (6%) actually required treatment during this 
period. Eyes that receive IVTA need to be monitored for IOP 
changes especially during the ﬁ  rst 3 months. However, IOP 
may still rise 6 months and even 12 months after a single 
injection. This study did not show any risk factors that may 
predict this IOP rise. Future studies need to look into the 
relationship between the dose of IVTA and IOP rise. The 
most clinically effective dose with the least side effects 
would be recommended.
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